Interstitial Lung Diseases (ILDs) encompass a broad category of around 200 lung disorders, characterized by inflammation and fibrosis of the pulmonary interstitium. They pose significant diagnostic and therapeutic challenges due to their complex etiologies and variable clinical presentations.
ILDs typically result from an aberrant repair response to alveolar epithelial injury. This response leads to fibroblast proliferation and extracellular matrix deposition, causing architectural distortion of the lung parenchyma. The etiology of ILDs is diverse, ranging from occupational and environmental exposures to systemic diseases, infections, and drugs. However, a substantial proportion of cases are idiopathic.
Patients with ILDs often present with non-specific symptoms such as progressive dyspnea and dry cough. Physical examination may reveal inspiratory crackles and finger clubbing. The diagnostic approach involves imaging studies, pulmonary function tests, and sometimes, lung biopsy. High-resolution computed tomography (HRCT) is particularly valuable in identifying characteristic patterns that suggest specific ILDs.
Management of ILDs is primarily aimed at reducing symptoms, slowing disease progression, and improving quality of life. This may involve the use of immunosuppressive drugs, antifibrotic agents, or lung transplantation in severe cases. In addition, supportive care measures such as oxygen therapy and pulmonary rehabilitation play a crucial role.
The prognosis of ILDs varies widely depending on the specific type and severity of the disease, as well as the patient's age and comorbid conditions. Idiopathic Pulmonary Fibrosis (IPF), one of the most common and severe forms of ILDs, has a median survival of 2-3 years from the time of diagnosis.
ILDs represent a complex group of diseases with diverse etiologies and clinical presentations. A comprehensive understanding of their pathogenesis, diagnosis, management, and prognosis is essential for healthcare professionals to provide optimal care for these patients.
1.
Regular physical activity before cancer diagnosis may lower progression and death risks
2.
Medication Self-Injection Embraced by Breast Cancer Patients
3.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
4.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
5.
ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs
1.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
2.
Clinical Pathways in Hematology in Clinical Decision-Making
3.
Immune Surveillance Screening for Early Cancer Risk Detection
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
AI-Driven Digital Pathology in Oncology: From Histology Images to Predictive Treatment Biomarkers
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Signs and Symptoms of Leukemia
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation